Equities research analysts expect that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will announce earnings of ($1.08) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Alder Biopharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.54) and the highest estimate coming in at ($0.87). Alder Biopharmaceuticals posted earnings per share of ($0.97) during the same quarter last year, which indicates a negative year over year growth rate of 11.3%. The firm is expected to issue its next quarterly earnings report after the market closes on Monday, February 26th.
According to Zacks, analysts expect that Alder Biopharmaceuticals will report full year earnings of ($5.45) per share for the current fiscal year, with EPS estimates ranging from ($5.94) to ($5.18). For the next fiscal year, analysts expect that the business will post earnings of ($3.90) per share, with EPS estimates ranging from ($5.42) to ($2.84). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Alder Biopharmaceuticals.
Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.23. The business had revenue of $0.94 million for the quarter. During the same quarter in the previous year, the firm earned ($0.97) earnings per share.
A number of research firms recently weighed in on ALDR. Cowen set a $23.00 target price on Alder Biopharmaceuticals and gave the stock a “buy” rating in a report on Monday. Mizuho reissued a “buy” rating and set a $29.00 target price on shares of Alder Biopharmaceuticals in a report on Wednesday, January 31st. Canaccord Genuity set a $22.00 target price on Alder Biopharmaceuticals and gave the stock a “buy” rating in a report on Friday, January 12th. BMO Capital Markets reissued a “buy” rating and set a $22.00 target price on shares of Alder Biopharmaceuticals in a report on Wednesday, January 3rd. Finally, BidaskClub raised Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 29th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the stock. Alder Biopharmaceuticals currently has an average rating of “Hold” and an average price target of $28.14.
Alder Biopharmaceuticals (NASDAQ ALDR) traded down $0.55 during mid-day trading on Friday, hitting $14.20. The company had a trading volume of 2,561,000 shares, compared to its average volume of 1,965,689. The firm has a market cap of $1,000.70, a price-to-earnings ratio of -2.65 and a beta of 2.60. Alder Biopharmaceuticals has a 1-year low of $8.60 and a 1-year high of $24.65.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Palo Alto Investors LLC lifted its position in shares of Alder Biopharmaceuticals by 2,757.5% during the 4th quarter. Palo Alto Investors LLC now owns 1,840,246 shares of the biopharmaceutical company’s stock valued at $21,071,000 after acquiring an additional 1,775,846 shares during the period. Carillon Tower Advisers Inc. bought a new stake in shares of Alder Biopharmaceuticals during the 4th quarter valued at $14,676,000. Pinnacle Associates Ltd. bought a new stake in shares of Alder Biopharmaceuticals during the 3rd quarter valued at $14,823,000. Pictet Asset Management Ltd. lifted its position in shares of Alder Biopharmaceuticals by 159.4% during the 3rd quarter. Pictet Asset Management Ltd. now owns 1,650,540 shares of the biopharmaceutical company’s stock valued at $20,219,000 after acquiring an additional 1,014,290 shares during the period. Finally, AXA lifted its position in shares of Alder Biopharmaceuticals by 199.9% during the 3rd quarter. AXA now owns 992,083 shares of the biopharmaceutical company’s stock valued at $12,153,000 after acquiring an additional 661,253 shares during the period. Institutional investors and hedge funds own 95.34% of the company’s stock.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.